- The Prediction of HER2-Targeted Treatment Response Using 64CuTetra- Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
-
Lee I, Lim I, Byun BH, Kim BI, Choi CW, Lee KC, Kang CM, Seong MK, Kim HA, Noh WC, Lim SM
- KMID: 2526725
- J Breast Cancer.
- 2022 Feb;25(1):69-73.
- doi: 10.4048/jbc.2022.25.e5
A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted... -
- CITED
-
- Close
- SHARE
-
- Close
- CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With FamTrastuzumab Deruxtecan: A Single Institutional Experience
-
Jang YJ, Jeong JH, Kim JE, Ahn JH, Jung KH, Kim SB
- KMID: 2526723
- J Breast Cancer.
- 2022 Feb;25(1):49-56.
- doi: 10.4048/jbc.2022.25.e1
This single-institute, retrospective cohort study enrolled patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab deruxtecan between August 2017 and January 2021 from four previous... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after BreastConserving Surgery
-
Cheun JH, Won J, Jung JG, Kim HK, Han W, Lee HB
- KMID: 2517344
- J Breast Cancer.
- 2021 Jun;24(3):301-314.
- doi: 10.4048/jbc.2021.24.e33
Purpose: Trastuzumab is effective in early and advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, few studies have reported the effect of trastuzumab on ipsilateral breast tumor... -
- CITED
-
- Close
- SHARE
-
- Close
- MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
-
Feng Q, Ren Y, Hou A, Guo J, Mao Z, Liu S, Wang B, Bai Z, Hou X
- KMID: 2515166
- J Breast Cancer.
- 2021 Apr;24(2):153-163.
- doi: 10.4048/jbc.2021.24.e15
Purpose: This study aimed to investigate the changes in microRNA-130a (miR-130a) and its correlation with cardiotoxicity during epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D+T) adjuvant chemotherapy in human epidermal growth... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting
-
Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK
- KMID: 2514925
- Cancer Res Treat.
- 2021 Apr;53(2):436-444.
- doi: 10.4143/crt.2020.725
Purpose This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Cutaneous Photosensitivity Possibly Induced by Paclitaxel and Trastuzumab
-
Lee HY, Jeon YJ, Koo DW, Lee JS
- KMID: 2512424
- Korean J Dermatol.
- 2021 Jan;59(1):77-79.
-
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy
-
Ha GY, Yang SH, Kang HJ, Lee HL, Kim J, Kim YJ, Yu HJ, Lee JI, Jin SH
- KMID: 2511167
- Korean J Clin Oncol.
- 2020 Dec;16(2):63-70.
- doi: 10.14216/kjco.20011
Purpose: Currently, trastuzumab plus chemotherapy is the standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (mGC) or esophagogastric junction cancer. However, it... -
- CITED
-
- Close
- SHARE
-
- Close
- Updated Bayesian Network MetaAnalysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer
-
Li X, Yao L, Wang M, Wang M, Li X, Yu X, Guo J, Dong H, Sun X, Xu Y
- KMID: 2511800
- J Breast Cancer.
- 2020 Aug;23(4):410-429.
- doi: 10.4048/jbc.2020.23.e45
Purpose: Combining targeted agents with adjuvant chemotherapy prolongs survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, but also increases the risk of adverse effects. The updated... -
- CITED
-
- Close
- SHARE
-
- Close
- Radioisotope-ADME studies of Trastuzumab-monomethyl auristatin F in tumor bearing mice and healthy marmosets
-
Lee HW, Jeong YH, Hwang JA, Lee JJ, Yu AR, Kang JA, Raza MA, Park SH, Park YH, Kim DH
- KMID: 2503833
- J Biomed Transl Res.
- 2020 Jun;21(2):79-90.
- doi: 10.12729/jbtr.2020.21.2.079
Radioisotope ADME (RI-ADME) studies are enabling visualization of the biodistribution in molecular imaging. We applied RI-ADME to investigate the tumor targeting capacity and biodistribution of trastuzumab-monomethyl auristatin F (LCB14-0110) in... -
- CITED
-
- Close
- SHARE
-
- Close
- Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
-
Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H
- KMID: 2511779
- J Breast Cancer.
- 2020 Jun;23(3):259-267.
- doi: 10.4048/jbc.2020.23.e34
Purpose: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term... -
- CITED
-
- Close
- SHARE
-
- Close
- Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection
-
Prieto M, Gastaca M, Ruiz P, Ventoso A, Palomares , Perfecto A, Valdivieso A
- KMID: 2464332
- Ann Hepatobiliary Pancreat Surg.
- 2019 Nov;23(4):403-407.
- doi: 10.14701/ahbps.2019.23.4.403
Surgery is the only treatment for biliary tract cancer with long term survival. Unfortunately, most patients are diagnosed at stage IV with distant metastases. In these circumstances, life expectancy is... -
- CITED
-
- Close
- SHARE
-
- Close
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
-
Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel , Ro J
- KMID: 2460601
- Cancer Res Treat.
- 2019 Oct;51(4):1527-1539.
- doi: 10.4143/crt.2018.598
PURPOSE: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
-
Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, Lee SC, Ahn JS, Park SW, Im YH, Jeon ES, Park YH
- KMID: 2464418
- Cancer Res Treat.
- 2019 Apr;51(2):727-736.
- doi: 10.4143/crt.2018.262
PURPOSE: While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study
-
Kim K, Shin KH, Kim JH, Choi DH, Park W, Kim YB, Kim HJ, Kim JH, Park H, Lee SY, Kim J, Oh DH, Kim IA
- KMID: 2441857
- J Breast Cancer.
- 2019 Mar;22(1):120-130.
- doi: 10.4048/jbc.2019.22.e1
PURPOSE: The purpose of this study was to evaluate the risk of central nervous system (CNS) failure in Korean patients with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
-
El-Enbaby , El Moneim , El atti Khedr GA, Elwany YM
- KMID: 2432608
- Korean J Clin Oncol.
- 2018 Dec;14(2):108-115.
- doi: 10.14216/kjco.18019
PURPOSE: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data
-
You SH, Chae BJ, Eom YH, Yoo TK, Kim YS, Kim JS, Park WC
- KMID: 2429820
- J Breast Cancer.
- 2018 Dec;21(4):415-424.
- doi: 10.4048/jbc.2018.21.e53
PURPOSE: Triple-positive breast cancer is defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity. Several systemic breast cancer therapies target hormonal and HER2 responsiveness.... -
- CITED
-
- Close
- SHARE
-
- Close
- FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment
-
Chae H, Yoo C, Yoon JA, Lee HJ, Kim KP, Kim JE, Ahn JH, Jung KH, Gong G, Kim SB
- KMID: 2441867
- J Breast Cancer.
- 2018 Mar;21(1):45-50.
- doi: 10.4048/jbc.2018.21.1.45
PURPOSE: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating... -
- CITED
-
- Close
- SHARE
-
- Close
- Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer
-
Min JW, Kang YD
- KMID: 2409129
- Perinatology.
- 2017 Dec;28(4):184-186.
- doi: 10.14734/PN.2017.28.4.184
Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor-2 positive breast cancer. There is a little information in the literature regarding the safe use... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
-
Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ
- KMID: 2379402
- J Breast Cancer.
- 2017 Mar;20(1):82-90.
- doi: 10.4048/jbc.2017.20.1.82
PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer
-
Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC
- KMID: 2362926
- J Breast Cancer.
- 2016 Dec;19(4):402-409.
- doi: 10.4048/jbc.2016.19.4.402
PURPOSE: As the numbers of cancer cases and survivors increase, the incidence and natural history of chemotherapy-induced cardiotoxicities in patients with breast cancer may also be expected to change. The... -
- CITED
-
- Close
- SHARE
-
- Close
